This market research report is based off of the data provided from 241 respondents who have been involved in outsourced small molecule projects over the past 18 months. It provides service quality evaluations on 36 CMOs across 27 critical attributes. These attributes include: Proven ability to manufacture small molecule API, Reliable on-time delivery, Strong regulatory track record, Track record for meeting quality performance metrics, Ability to smoothly scale up manufacturing and transfer technology, Scientific knowledge, among others. The respondents provided assessment ratings based off of 689 total service encounters.
This report includes information on buyers’ outsourcing philosophies and practices specific to small molecule projects, their perceptions of (and experiences with) certain contract manufacturers, and their CMO selection criteria. Data includes in-depth analysis on AbbVie Contract Manufacturing, Aesica, Albany Molecular Research Inc. (AMRI), Alcami, Almac, AMPAC Fine Chemicals, Aptuit, Ash Stevens, Cambrex, Dr. Reddy’s CPS, Evonik, GSK Contract Manufacturing, Halo Pharma, Lonza, Novasep, Patheon, Pfizer CentreOne, PharmaCore, Piramal Pharma Solutions, Recipharm, SAFC, SAI Life Sciences, Sanofi CEPiA, Siegfried, Wockhardt and Wuxi AppTec.
Drug developers can use this report to make an educated purchase of CMO services by getting insight into how some manufacturers have measured up to sponsor-peer expectations on small molecule API projects. They’ll also get insight into which CMO attributes are driving outsourcing partner selection amongst their peers.
Contract manufacturers can use the report to compare their company’s performance against their competitors specific to small molecule API and related services, gain insight into sponsors outsourcing preferences for small molecule manufacturing projects, and uncover their perceived strengths and weaknesses amongst their customer base.
Download the preview file for more information.